BTK and diffuse large B-cell lymphoma: With the purpose of ameliorate PHOENIX results, ESCALADE (NCT04529772) is a phase III trial randomized to perform R-CHOP or R-CHOP plus acalabrutinib on young untreated non-GCB DLBCL patients (65 years old), a selective second-generation BTK inhibitor with fewer off-target side effects [151].